Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer - Sensei Biotherapeutics (NASDAQ:SNSE)

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer

Related Keywords

Boston ,Massachusetts ,United States ,Chris Railey ,Sensei Biotherapeutics ,Michael Biega ,John Celebi ,Stephanie Krebs ,Johns Hopkins University ,University Of Rochester ,Exchange Commission ,Valo Health ,Sensei Biotherapeutics Inc ,Chief Business ,Chief Business Officer ,Hotspot Therapeutics ,Swedish Orphan Biovitrum ,Chief Executive Officer ,Tumor Microenvironment Activated ,Immunoglobulin Domain Containing ,Private Securities Litigation Reform Act ,Quarterly Report ,Periodic Reports ,